Alto Neuroscience, Inc. Convertible Debt
Alto Neuroscience, Inc. (ANRO) had Convertible Debt of $2.46 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:ConvertibleDebt · last filed 2026-08-12
- 2026-06-30: Convertible Debt $2.46M.
- 2026-03-31: Convertible Debt $2.33M.
- 2025-12-31: Convertible Debt $2.23M.
- 2025-09-30: Convertible Debt $2.12M.
| Period end | Convertible Debt |
|---|---|
| 2026-06-30 | $2.46M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $2.33M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $2.23M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $2.12M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.00M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $1.21M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.30M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.30M 10-Q · filed 2024-11-12 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |